Wet Macular Degeneration
COAST (Sponsor: Opthea)
2018-Present
Clinical Trial Protocol Number: OPT-302-1005
A Phase 3, Multicenter, Double-masked, Randomized Study to Evaluate the Efficacy and Safety of Intravitreal OPT-302 in Combination with Aflibercept, Compared with Aflibercept Alone, in Participants with Neovascular Age-related Macular Degeneration (nAMD)
Dry Macular Degeneration
Gallego (Sponsor: Genentech, Inc.)
2019-Present
Clinical Trial Protocol Number: GR40973
A PHASE II, MULTICENTER, RANDOMIZED, SINGLE-MASKED, SHAM−CONTROLLED STUDY TO ASSESS SAFETY, TOLERABILITY, AND EFFICACY OF INTRAVITREAL INJECTIONS OF FHTR2163 IN PATIENTS WITH GEOGRAPHIC ATROPHY SECONDARY TO AGE-RELATED MACULAR DEGENERATION
Diabetic Macular Edema
Rhone-X (Sponsor: Genentech)
2021-Current
Clinical Trial Protocol Number: GR41987
A Multicenter, Open-label extension study to evaluate the long-term safety and tolerability of Faricimab in patients with Diabetic Macular Edema
Diabetic Retinopathy
FOCUS (Sponsor: Novo Nordisk)
2019-Present
Clinical Trial Protocol Number: NN9535-4352
This Trial Is A Randomized, Double-Blinded, Parallel-Group, Placebo-Controlled Trial To Assess The Long-Term Effects Of Treatment With Semaglutide Compared To Placebo, Both Added To Standard-Of-Care, On Diabetic Retinopathy Development And Progression In Subjects With Type 2 Diabetes.
Retinal Vein Occlusion
COMINO (Sponsor: Genentech)
2021-Current
Clinical Trial Protocol Number: GR41986
A Phase 3, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled study to evaluate the Efficacy and Safety of Faricimab in patients with Macular Edema Secondary to Central Retina or Hemiretinal Vein Occlusion
Beacon (Sponsor: Kodiak)
2021-Current
Clinical Trial Protocol Number: KS301P103
A Prospective, Randomized, Double-masked, Active Comparator-controlled, Multi-center, Two-arm, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 Compared with Intravitreal Aflibercept in Participants with Visual Impairment Due to Treatment-naïve Macular Edema Secondary to Retinal Vein Occlusion